Long-term outcome for patients with non-metastatic Ewing's sarcoma treated with adjuvant and neoadjuvant chemotherapies. 402 patients treated at Rizzoli between 1972 and 1992

Bacci, Gaetano; Forni, Cristiana; Longhi, Alessandra; Ferrari, Stefano; Donati, Davide María; Barbieri, Enza; Pignotti, Elettra; Rosito, P; Versari, Michela

doi:10.1016/j.ejca.2003.08.022

Cited by 150 publications

(117 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Previous research showed that childhood survivors of osteosarcoma and Ewing's sarcoma have increased subsequent risk of having an additional primary cancer develop [8], and this is likely contributory to the remote cause-specific mortality reflected in our data. Further evidence for late mortality after a pediatric malignancy attributable to recurrence or spread of the primary cancer, subsequent malignancy, or treatment-related complications has been reported [1,2,26,28], and our data support this concern.…”

Section: Discussionsupporting

confidence: 78%

“…The survival rates in our cohort improved with time, but not to the point where cancer cause-specific mortality was negated. Previous studies have recommended lifelong surveillance for patients with osteosarcoma and Ewing's sarcoma to monitor for late dissemination, recurrence, and secondary malignancy [2,26,28]. More specifically, the National Comprehensive Cancer Network recommends clinical and radiographic followups for patients with osteosarcoma every 3 months for Years 1 and 2, every 4 months for Year 3, every 6 months for Years 4 and 5, and annually thereafter [24].…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Conditional Survival Is Greater Than Overall Survival at Diagnosis in Patients With Osteosarcoma and Ewing’s Sarcoma

Miller

Lynch

Buckwalter

2013

Clinical Orthopaedics &Amp; Related Research

View full text Add to dashboard Cite

Background Conditional survival is a measure of the risk of mortality given that a patient has survived a defined period of time. These estimates are clinically helpful, but have not been reported previously for osteosarcoma or Ewing's sarcoma. Questions/purposes We determined the conditional survival of patients with osteosarcoma and Ewing's sarcoma given survival of 1 or more years. Methods We used the Surveillance, Epidemiology, and End Results (SEER) Program database to investigate cases of osteosarcoma and Ewing's sarcoma in patients younger than 40 years from 1973 to 2009. The SEER Program is managed by the National Cancer Institute and provides survival data gathered from population-based cancer registries. We used an actuarial life table analysis to determine any cancer cause-specific 5-year survival estimates conditional on 1 to 5 years of survival after diagnosis. We performed a similar analysis to determine 20-year survival from the time of diagnosis. Results The estimated 5-year survival improved each year after diagnosis. For local/regional osteosarcoma, the 5-year survival improved from 74.8% at baseline to 91.4% at 5 years-meaning that if a patient with localized osteosarcoma lives for 5 years, the chance of living for another 5 years is 91.4%. Similarly, the 5-year survivals for local/regional Ewing's sarcoma improved from 72.9% at baseline to 92.5% at 5 years, for metastatic osteosarcoma 35.5% at baseline to 85.4% at 5 years, and for metastatic Ewing's sarcoma 31.7% at baseline to 83.6% at 5 years. The likelihood of 20-year cause-specific survival from the time of diagnosis in osteosarcoma and Ewing's sarcoma was almost 90% or greater after 10 years of survival, suggesting that while most patients will remain disease-free indefinitely, some experience cancerrelated complications years after presumed eradication. Conclusions The 5-year survival estimates of osteosarcoma and Ewing's sarcoma improve with each additional year of patient survival. Knowledge of a changing risk profile is useful in counseling patients with time.

show abstract

Section: Discussionsupporting

confidence: 78%

Section: Discussionmentioning

confidence: 99%

Conditional Survival Is Greater Than Overall Survival at Diagnosis in Patients With Osteosarcoma and Ewing’s Sarcoma

Miller

Lynch

Buckwalter

2013

Clinical Orthopaedics &Amp; Related Research

View full text Add to dashboard Cite

show abstract

“…1 -костная ткань, 2 -хрящевая ткань (ϫ4 вичной опухоли и/или очагов, подозрительных на мета-статические (рис. 22,23), МРТ с внутривенным контра-стированием пораженной кости и смежных суставов (рис. 24, 25), а также радиоизотопного исследования костей скелета (рис.…”

Section: опухоли костейunclassified

Malignant Neoplasms in Children: Clinical Manifestations and Diagnosis

Rykov¹,

Севрюков²,

Vyalov³

2017

Vopr. sovr. pediatr.

View full text Add to dashboard Cite

“…Все эти саркомы происхо-дят из общего мезенхимального источника, имеют общие генетические поломки и являются высо-коагрессивными новообразованиями с высо-ким потенциалом развития и метастазирования [1][2][3][4]. Локализованные (неметастатические) фор-мы составляют более 70% всех СЮ, но около 1/3 случаев демонстрируют резистентность опухоли, несмотря на использование различных вариан-тов полихимиотерапии на протяжении последних десятилетий [5,6].…”

Section: обоснованиеunclassified

Molecular Markers of Angiogenesis as a Basis for the Use of Vegf Blockade in Patients With Localized Ewing’s Sarcoma

Киселёв¹,

Савицкая²,

Алейникова³

2017

Oncopediatria

View full text Add to dashboard Cite

Long-term outcome for patients with non-metastatic Ewing's sarcoma treated with adjuvant and neoadjuvant chemotherapies. 402 patients treated at Rizzoli between 1972 and 1992

Cited by 150 publications

References 36 publications

Conditional Survival Is Greater Than Overall Survival at Diagnosis in Patients With Osteosarcoma and Ewing’s Sarcoma

Conditional Survival Is Greater Than Overall Survival at Diagnosis in Patients With Osteosarcoma and Ewing’s Sarcoma

Malignant Neoplasms in Children: Clinical Manifestations and Diagnosis

Molecular Markers of Angiogenesis as a Basis for the Use of Vegf Blockade in Patients With Localized Ewing’s Sarcoma

Contact Info

Product

Resources

About